Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer
Most cells express a variety of both anti-apoptotic and pro-apoptotic Bcl-2 proteins and the interaction within this family dictates whether a cell survives or dies. The dysregulation of the anti-anti-apoptotic Bcl-2 family members is one of the defining features of cancer cells in comparison to nor...
Збережено в:
| Дата: | 2012 |
|---|---|
| Автори: | , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2012
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/139083 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer / B. Weyhenmeyer, A.C. Murphy, J.H.M. Prehn, B.M. Murphy // Experimental Oncology. — 2012. — Т. 34, № 3. — С. 192-199. — Бібліогр.: 108 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-139083 |
|---|---|
| record_format |
dspace |
| spelling |
irk-123456789-1390832018-06-20T03:04:49Z Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer Weyhenmeyer, B. Murphy, A.C. Prehn, J.H.M. Murphy, B.M. Reviews Most cells express a variety of both anti-apoptotic and pro-apoptotic Bcl-2 proteins and the interaction within this family dictates whether a cell survives or dies. The dysregulation of the anti-anti-apoptotic Bcl-2 family members is one of the defining features of cancer cells in comparison to normal cells, and significantly contributes to the resistance of cancer cells to current treatment modalities. This anti-apoptotic subfamily of proteins is now a major target in the development of new methods to improve treatment outcomes for cancer patients. Several drugs directed at inhibiting Bcl-2 and related anti-apoptotic proteins have been developed with some showing considerable promise in the clinic. This Review presents the current knowledge of the role of the anti-apoptotic Bcl-2 family in cancer cells, as well as current and future perspectives on targeting this subfamily of proteins for therapeutic intervention in human malignancies. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”. 2012 Article Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer / B. Weyhenmeyer, A.C. Murphy, J.H.M. Prehn, B.M. Murphy // Experimental Oncology. — 2012. — Т. 34, № 3. — С. 192-199. — Бібліогр.: 108 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/139083 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Reviews Reviews |
| spellingShingle |
Reviews Reviews Weyhenmeyer, B. Murphy, A.C. Prehn, J.H.M. Murphy, B.M. Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer Experimental Oncology |
| description |
Most cells express a variety of both anti-apoptotic and pro-apoptotic Bcl-2 proteins and the interaction within this family dictates whether a cell survives or dies. The dysregulation of the anti-anti-apoptotic Bcl-2 family members is one of the defining features of cancer cells in comparison to normal cells, and significantly contributes to the resistance of cancer cells to current treatment modalities. This anti-apoptotic subfamily of proteins is now a major target in the development of new methods to improve treatment outcomes for cancer patients. Several drugs directed at inhibiting Bcl-2 and related anti-apoptotic proteins have been developed with some showing considerable promise in the clinic. This Review presents the current knowledge of the role of the anti-apoptotic Bcl-2 family in cancer cells, as well as current and future perspectives on targeting this subfamily of proteins for therapeutic intervention in human malignancies. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”. |
| format |
Article |
| author |
Weyhenmeyer, B. Murphy, A.C. Prehn, J.H.M. Murphy, B.M. |
| author_facet |
Weyhenmeyer, B. Murphy, A.C. Prehn, J.H.M. Murphy, B.M. |
| author_sort |
Weyhenmeyer, B. |
| title |
Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer |
| title_short |
Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer |
| title_full |
Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer |
| title_fullStr |
Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer |
| title_full_unstemmed |
Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer |
| title_sort |
targeting the anti-apoptotic bcl-2 family members for the treatment of cancer |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2012 |
| topic_facet |
Reviews |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/139083 |
| citation_txt |
Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer / B. Weyhenmeyer, A.C. Murphy, J.H.M. Prehn, B.M. Murphy // Experimental Oncology. — 2012. — Т. 34, № 3. — С. 192-199. — Бібліогр.: 108 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT weyhenmeyerb targetingtheantiapoptoticbcl2familymembersforthetreatmentofcancer AT murphyac targetingtheantiapoptoticbcl2familymembersforthetreatmentofcancer AT prehnjhm targetingtheantiapoptoticbcl2familymembersforthetreatmentofcancer AT murphybm targetingtheantiapoptoticbcl2familymembersforthetreatmentofcancer |
| first_indexed |
2023-10-18T21:19:36Z |
| last_indexed |
2023-10-18T21:19:36Z |
| _version_ |
1796152514966454272 |